429 related articles for article (PubMed ID: 12631626)
21. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
22. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
23. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
24. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
25. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
Mellinghoff IK; Tran C; Sawyers CL
Cancer Res; 2002 Sep; 62(18):5254-9. PubMed ID: 12234993
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha.
Miyake K; Tsuchida K; Sugino H; Imura S; Morine Y; Fujii M; Shimada M
Cancer Chemother Pharmacol; 2007 Jan; 59(1):113-26. PubMed ID: 16699793
[TBL] [Abstract][Full Text] [Related]
27. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN
Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
[TBL] [Abstract][Full Text] [Related]
29. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.
Radinsky R; Risin S; Fan D; Dong Z; Bielenberg D; Bucana CD; Fidler IJ
Clin Cancer Res; 1995 Jan; 1(1):19-31. PubMed ID: 9815883
[TBL] [Abstract][Full Text] [Related]
30. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
Kedar D; Baker CH; Killion JJ; Dinney CP; Fidler IJ
Clin Cancer Res; 2002 Nov; 8(11):3592-600. PubMed ID: 12429651
[TBL] [Abstract][Full Text] [Related]
31. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
Levine L; Lucci JA; Pazdrak B; Cheng JZ; Guo YS; Townsend CM; Hellmich MR
Cancer Res; 2003 Jul; 63(13):3495-502. PubMed ID: 12839933
[TBL] [Abstract][Full Text] [Related]
32. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
Kim SJ; Uehara H; Yazici S; Busby JE; Nakamura T; He J; Maya M; Logothetis C; Mathew P; Wang X; Do KA; Fan D; Fidler IJ
J Natl Cancer Inst; 2006 Jun; 98(11):783-93. PubMed ID: 16757703
[TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
Dorai T; Gehani N; Katz A
Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300
[TBL] [Abstract][Full Text] [Related]
36. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
37. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.
Inoue K; Slaton JW; Eve BY; Kim SJ; Perrotte P; Balbay MD; Yano S; Bar-Eli M; Radinsky R; Pettaway CA; Dinney CP
Clin Cancer Res; 2000 May; 6(5):2104-19. PubMed ID: 10815938
[TBL] [Abstract][Full Text] [Related]
39. Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
Harper ME; Goddard L; Glynne-Jones E; Assender J; Dutkowski CM; Barrow D; Dewhurst OL; Wakeling AE; Nicholson RI
Prostate; 2002 Jun; 52(1):59-68. PubMed ID: 11992620
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
